0
settings
الوضع الليلي
moon
انماط الصفحة الرئيسية arrow
EN
1
المرجع الالكتروني للمعلوماتية

النبات

مواضيع عامة في علم النبات

الجذور - السيقان - الأوراق

النباتات الوعائية واللاوعائية

البذور (مغطاة البذور - عاريات البذور)

الطحالب

النباتات الطبية

الحيوان

مواضيع عامة في علم الحيوان

علم التشريح

التنوع الإحيائي

البايلوجيا الخلوية

الأحياء المجهرية

البكتيريا

الفطريات

الطفيليات

الفايروسات

علم الأمراض

الاورام

الامراض الوراثية

الامراض المناعية

الامراض المدارية

اضطرابات الدورة الدموية

مواضيع عامة في علم الامراض

الحشرات

التقانة الإحيائية

مواضيع عامة في التقانة الإحيائية

التقنية الحيوية المكروبية

التقنية الحيوية والميكروبات

الفعاليات الحيوية

وراثة الاحياء المجهرية

تصنيف الاحياء المجهرية

الاحياء المجهرية في الطبيعة

أيض الاجهاد

التقنية الحيوية والبيئة

التقنية الحيوية والطب

التقنية الحيوية والزراعة

التقنية الحيوية والصناعة

التقنية الحيوية والطاقة

البحار والطحالب الصغيرة

عزل البروتين

هندسة الجينات

التقنية الحياتية النانوية

مفاهيم التقنية الحيوية النانوية

التراكيب النانوية والمجاهر المستخدمة في رؤيتها

تصنيع وتخليق المواد النانوية

تطبيقات التقنية النانوية والحيوية النانوية

الرقائق والمتحسسات الحيوية

المصفوفات المجهرية وحاسوب الدنا

اللقاحات

البيئة والتلوث

علم الأجنة

اعضاء التكاثر وتشكل الاعراس

الاخصاب

التشطر

العصيبة وتشكل الجسيدات

تشكل اللواحق الجنينية

تكون المعيدة وظهور الطبقات الجنينية

مقدمة لعلم الاجنة

الأحياء الجزيئي

مواضيع عامة في الاحياء الجزيئي

علم وظائف الأعضاء

الغدد

مواضيع عامة في الغدد

الغدد الصم و هرموناتها

الجسم تحت السريري

الغدة النخامية

الغدة الكظرية

الغدة التناسلية

الغدة الدرقية والجار الدرقية

الغدة البنكرياسية

الغدة الصنوبرية

مواضيع عامة في علم وظائف الاعضاء

الخلية الحيوانية

الجهاز العصبي

أعضاء الحس

الجهاز العضلي

السوائل الجسمية

الجهاز الدوري والليمف

الجهاز التنفسي

الجهاز الهضمي

الجهاز البولي

المضادات الميكروبية

مواضيع عامة في المضادات الميكروبية

مضادات البكتيريا

مضادات الفطريات

مضادات الطفيليات

مضادات الفايروسات

علم الخلية

الوراثة

الأحياء العامة

المناعة

التحليلات المرضية

الكيمياء الحيوية

مواضيع متنوعة أخرى

الانزيمات

قم بتسجيل الدخول اولاً لكي يتسنى لك الاعجاب والتعليق.

Rheumatoid arthritis

المؤلف:  Siraj A. Misbah, Gavin P. Spickett, and Virgil A. S. H. Dalm

المصدر:  Chapel and Haeneys Essentials of Clinical Immunology (2022)

الجزء والصفحة:  7th edition , P198-203

2026-11-18

162

+

-

20

Diagnosis

RA is a common disease affecting 1–2% of the adult population and is twice as common in women as men. It is most common between the ages of 25 and 55 years, and the most frequent presentation is an insidious, symmetrical polyarthritis, although the disease can begin abruptly. Although systemic manifestations (Table 1) may be present at the outset, they develop more usually as the disease progresses. The diagnosis of RA is made on clinical grounds.

Table1. Extraarticular features of rheumatoid arthritis (RA): the commonest features are marked in bold

Serology

A test measuring levels of antibodies that bind citrulline modified proteins (anti- CCP) is used in the diagnostic work up for RA. It is specific for rheumatoid disease, as it is elevated in patients with RA or in those about to develop RA and not in other forms of arthritis (see later in the text).

Patients with RA fall into two groups: those with usually less severe disease who lack circulating rheumatoid factor (RF) (seronegative RA); and a larger group (70%) with more aggressive disease who have, or develop, a RF in the serum (seropositive RA). Extraarticular disease occurs predominantly in this seropositive group. RF is of value in diagnosis and prognosis, but is not of sufficient specificity alone to establish the diagnosis of RA. RF, in this context, refers only to the IgM antibody that binds aggregated IgG as its antigen; rheumatoid factors of the IgG or IgA class are not clinically helpful, although they may play a role in joint inflammation. The presence of anti- CCP antibodies can also be used to predict which patients will get more severe RA. Other serological tests are of little value in RA. Antinuclear antibody (ANA) is present in 40%, but is usually of low titre and often of IgM class; such ANAs are found in many other conditions. Serum complement C3 and C4 levels may be normal or raised due to an ‘acute- phase’ reaction.

C- reactive protein (CRP) (another ‘acute- phase’ reactant) is an important test in any inflammatory arthritis, being raised particularly in active RA; this helps to distinguish active RA from active SLE, in which there is not an acute- phase response. Also erythrocyte sedimentation rate (ESR) values can be measured, which tend to correlate with disease activity and severity in RA. Radiological damage is more likely to progress when CRP and ESR are elevated.

Pathology

The earliest pathological change in RA appears to be an infiltrate of neutrophils and mononuclear cells around small blood vessels in the loose connective tissue beneath the synovium. As the disease progresses, large numbers of T cells, macrophages, B cells and plasma cells accumulate in this tis sue, and the synovium becomes markedly thickened due to fibroblast proliferation and macrophage migration. The sur face area increases and becomes folded into villi. New vessel formation (angiogenesis) occurs and some blood vessels develop into structures specialized for lymphocyte migration: so- called high endothelial venules. Secondary lymphoid follicles also develop. In consequence, the histological structure comes to resemble that of an activated lymph node, emphasizing the high degree of immunological activity in RA. Increased amounts of synovial fluid can form (especially in large joints), and this contains large numbers of neutrophil polymorphs, which have migrated from the blood.

This chronic inflammatory tissue has several destructive effects upon the joint. First, the hypertrophied lining layer at the margins of the joint (known as pannus) erodes cartilage and underlying bone. Second, cytokines induce chondrocytes and fibroblasts to produce enzymes that break down the extra cellular matrix. Third, degranulation of neutrophils in the synovial fluid can directly damage the surface of cartilage (Fig. 1).

Fig1. Diagrammatic representation of a joint. One side is normal, the other shows characteristic pathological features of rheumatoid arthritis.

Immunopathogenesis

The immunohistology of rheumatoid synovium suggests that the disease results from an immunological response to an unknown antigen within the joint. It is, however, clear that joint destruction in RA is driven by activated macrophages (Fig. 2), which secrete TNF- α and other cytokines to cause tissue breakdown directly as well as activating other cells in the joint. A large number of inflammatory mediators are produced in RA synovium (Fig. 2), and early descriptions of cytokine production in RA talked of a ‘cytokine soup’, suggesting no simple way of inhibiting this process. However TNF- α plays a central role (Fig. 3), since inhibition with neutralizing antibodies reduces the production of other inflammatory mediators in cell culture. Furthermore, when these antibodies are administered to patients, a dramatic improvement in joint inflammation occurs. The members of the interleukin (IL)- 1 family, IL- 1α and IL- 1β, also play an important role, although a less crucial one than TNF.

Fig2. How CD4+ T cells and immune complexes may control the events leading to joint damage in rheumatoid arthritis. GM- CSF, granulocyte macrophage colony- stimulating factor; IL, interleukin; TNF, tumour necrosis factor.

Fig3. The central role of tumour necrosis factor (TNF)- α in rheumatoid synovial inflammation. IL, interleukin.

There is probably more than one immunological mechanism leading to macrophage activation in rheumatoid synovium. The most widely accepted model is a process driven by CD4+ Th1 cells. The evidence for T- cell involvement in RA is summarized in Table 10.5. However, the model of RA as a T- cell- driven disease has been criticized, as T- cell cytokines such as IL- 2 and interferon (IFN)- γ are hard to detect in RA synovium, in contrast to macrophage- derived cytokines such as TNF- α, IL- 1 and IL- 6, IL- 21 and IL- 23, which are present in abundance. Following the descriptions of Th17 cells being central to inflammation and RA being an inflammatory disease par excellence, the role of these cells makes sense given the pathology. Th17 cells form a subset that produces IL- 17A, IL- 17F, IL- 21 and IL- 22 as well as TNF- α. Th17 differentiation is promoted by macrophage- and dendritic cell- derived trans forming growth factor (TGF)- β as well as the cytokines mentioned, IL- 1β, IL- 6, IL- 21 and IL- 23. At the same time regulatory T cells (Tregs) are suppressed, shifting T- cell homeostasis toward inflammation. Th17 cells primarily produce IL- 17A, which together with TNF- α activates fibroblasts and chondrocytes. Foxp3+ Tregs, although detected in tissues from patients with RA, have limited function.

Inflammation driven by antibodies may also be important. The synovium is infiltrated by B cells and may even form ectopic lymphoid follicles. Plasmablasts and plasma cells are widely distributed in the synovium and in juxtaarticular bone marrow. Clinical demonstration that depletion of B cells (with an anti- CD20 monoclonal antibody, rituximab ) dramatically improves the clinical features of RA in a subset of patients shows that antibody- mediated inflammation does play a crucial role in the disease (Table 2), though the elimination of activated B cells that can present autoantigen to more T cells and produce inflammatory cytokines such as IL- 6 is important too. The role of innate immunity is uncertain as yet, but the ability of macrophages and neutrophils to be activated directly by triggering factors, through Toll- like receptors (TLRs) or intracellular receptors, to produce inflammatory cytokines is likely as the monoclonal antibody tocilizumab, an IL- 6 receptor inhibitor, has been shown to have excellent clinical effects.

Table2. Evidence that T and B cells play a central role in the pathogenesis of rheumatoid arthritis (RA)

Since RA is an immunologically mediated disease, then it should be possible to define the main antigens driving the T- and B- cell responses in the joint. These autoantigens could be self- molecules expressed in the joint or could be foreign (e.g. bacterial or viral) antigens sequestered in joint tissue. T- and B- cell responses to a number of autoantigens have been described in RA (Table 3), but most are not specific for RA and the role of responses against these antigens in the disease is unclear. One of the most plausible autoimmune models of RA would be for the disease to be driven by an immune response against an antigen whose expression is confined to joints, such as type II collagen, the main protein of articular cartilage. However, although immune responses against cartilage and synovial proteins can be found in some patients with RA, these are not found in all patients and are also found in other dis eases. Antibodies against a number of peptides containing the unusual amino acid citrulline (known as anticyclic citrullinated peptide antibodies, CCP antibodies) have recently been found to be highly specific to RA and to predict aggressive and persistent disease. It seems likely that RA is not caused by a single antigen, but rather by a response against a range of ‘citrullinated’ joint- specific proteins in genetically susceptible patients. In patients with the ‘shared epitope’, smoking produces detectable citrullinated pro teins in the lungs, mechanistically linking genetic and environmental risk factors.

Table3. Autoimmune responses identified in patients with rheumatoid arthritis (RA)

There is also evidence that macrophage- induced inflammation can become self- sustaining and independent of any triggering immune response: cytokines such as TNF- α produced by macrophages induce further macrophage activation. It is plausible that different mechanisms may predominate at different stages of this chronic disease.

Aetiology

In Europeans there is an association between possession of HLA- DR4 and - DR1 and RF- positive RA. This association becomes stronger with increasing severity of disease, and the presence of extraarticular manifestations (Table 1). Once the detailed structure of DR molecules was known at the amino acid level, comparison of different DR alleles associated with RA showed that almost all alleles associated with RA (HLA- DRB1*0101, 0401 and 0404) have a distinctive five amino acid sequence near the peptide- binding region of the DRβ chain; this sequence is known as the ‘shared epitope’. Possession of two copies of the ‘shared epitope’ (one inherited from each parent) is not only associated with a high risk of severe disease (Table 4), but also with presence of anti- CCP antibodies. Genome- wide association studies have shown that other genes involved in T- cell activation and the NFκB inflammation pathways are important. Female sex is an important genetic risk factor, and it seems plausible that this risk is mediated hormonally, as there is an increased risk of onset of RA in the post- partum period.

Table4. How possession of an HLA- DRB1 allele containing the ‘shared epitope’ influences absolute risk of developing rheumatoid arthritis (RA) in a Caucasian population

Environmental factors predisposing to RA remain poorly understood. Smoking is a relatively weak risk factor, but can increase the risk of RA 20- to 40- fold in genetically susceptible individuals. Many attempts have been made to link RA to infectious agents such as parvovirus, Epstein–Barr virus, mycoplasma and mycobacteria. However, while the idea of RA as a disease either initiated or perpetuated by an immune response against an infection has many attractions, no convincing evidence exists to implicate any known agent (see Chapter 5 for discussion of how infections may trigger autoimmunity).

Many animal models of RA have been developed, centred on both infection and autoimmunity, all with some similarity to the human disease. If nothing else, these models emphasize that the synovial response to injury is limited in scope and most of the aetiological factors are plausible and not mutually exclusive.

Outcome

Although the outcome of RA is variable and a few patients have mild or remitting disease, for most it is a severe and disabling illness. Most (70%) of RA patients have many periods of remission and relapse over decades though sustained remission is rarely achieved. Joint damage begins in the early stages of the disease and once established is effectively irreversible. Early studies suggested that 5 years after diagnosis, one- third of patients are unable to work at all and only one- third are still in full- time work. Subsequent surveys have shown that treatment with biologics was associated with a 35% increase in employment rate. Factors predicting a poor prognosis are detailed in Table 5.

Table5. Predictors of a poor prognosis in early rheumatoid arthritis

RA is associated with increased mortality as well as disability. Life expectancy in RA is reduced by approximately 7 years compared with age- and sex- matched controls. In severe, disabling RA, the 5- year mortality is around 50%. The causes of these premature deaths are multiple and in general not directly attributable to the arthritis, although some patients die of extraarticular disease such as pulmonary fibrosis, vasculitis, amyloid or lymphoma and others from the side effects of drug treatment. Patients with RA also show an increased susceptibility to severe or recurrent infection. The largest single contributor to increased mortality in RA is, however, an increased risk of ischaemic heart disease (IHD). Mortality from IHD in RA is increased by approximately two- to threefold, a comparable increase in risk to that seen in diabetes mellitus. Similar increased mortality from IHD has also been described in other chronic inflammatory diseases, particularly SLE. The mechanisms underlying this increased risk are unclear, but conventional risk factors alone (such as smoking, hyperlipidaemia and hypertension) cannot explain the increased risk, and immunosuppressive treatment and disease- specific factors make substantial contributions.

Management

Although management of RA is a multidisciplinary process, aiming to control the disease and minimize pain and disability, the paramount aim of treatment is the pharmacological limitation of joint inflammation and damage, using drugs that modify the natural history of the disease (disease- modifying antirheumatic drugs, DMARDs). Joint damage in RA begins early, is effectively irreversible and has a poor outcome: these are compelling reasons to introduce effective, aggressive treatment early in the disease.

Recognition of these factors has led to early use of disease- modifying drugs, particularly in subjects felt to have a poor prognosis; in addition to anti- TNF agents, methotrexate, leflunomide and sulfasalazine are commonly used drugs. There is an increasing tendency to use drugs in combi nation in severe or aggressive disease; these combinations are more effective and often no more toxic than single drug regimens. The goal is to achieve low disease activity (determined by affected joints) within 3–6 months to prevent irreversible damage. If this fails, another conventional DMARD is added or the patient is switched to another DMARD plus a glucocorticoid.

Patients who have failed treatment with methotrexate and similar drugs within 6 months, or those that have a poor prognosis (Table 5), are now usually treated with anti- TNF agents, such as etanercept and infliximab, which can control RA in >70% of patients. Dramatic responses in patients with refractory disease have also been reported following treatment with the anti- B- cell monoclonal antibody, rituximab. Recombinant IL- 1 receptor antagonist has also been used to block the action of IL- 1α and IL- 1β, but the response is not as striking as that seen with anti- TNF agents. Other biological agents approved for RA therapy include tocilizumab (anti- IL- 6), and the co- stimulation blocking agent abatacept (CTLA4- Ig). Janus kinase (JAK) inhibitors have been recently introduced in RA, either alone or in combination with methotrexate, and may be appropriate for patients who prefer to avoid medications requiring intravenous or subcutaneous administration. Small numbers of patients have been treated with highly aggressive chemotherapy and autologous stem cell transplantation with some success, but the long- term utility of this approach is not yet clear.

اخر الاخبار

اشترك بقناتنا على التلجرام ليصلك كل ما هو جديد